Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WSSO (Withania somnifera seed oil) is a supercritical fluid extract derived from the seeds of the Ashwagandha plant (*Withania somnifera*). It is characterized by a high content of fatty acids, primarily linoleic acid (54.15%), oleic acid (23.16%), and palmitic acid (12.64%), along with trace amounts of withanolides such as Withaferin A and Withanolide A. Developed by the Patanjali Research Institute, WSSO exhibits potent anti-inflammatory and anti-psoriatic activities. Its therapeutic effects are mediated through the inhibition of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and the suppression of the NF-κB signaling pathway. Preclinical studies in mouse models have shown that topical application of WSSO reduces ear edema, epidermal thickness, and myeloperoxidase (MPO) activity, effectively repairing psoriasis-like skin lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Withania somnifera seed oil.